Norwegian Research Council awards MNOK 11.3 for new ARIA project

The project builds on the use of our inhouse-developed assays for a new application in Alzheimer’s disease. The aim is to develop a novel biomarker system to detect and monitor severe adverse side effects of new immunotherapies for Alzheimer’s. These immunotherapies have demonstrated promising effect in clinical trials, and four new treatments have filed for FDA approval. Yet, these severe side effects, known as ARIA (Amyloid-Related Imaging Abnormalities, brain haemorrhaging) occur in up to 40% of patients on high doses are not addressed with current diagnostic tools.